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Introduction
Prostate cancer (PCa) is the most common non-cutaneous 
cancer among men in the United States. In 2018, it is 
estimated that more than 169,000 men will be diagnosed 
with prostate cancer and there will be more than 29,000 
deaths from the disease in the United States (1). While 
there is considerable morbidity and mortality as a result 
of prostate cancer, a significant population of men with 
prostate cancer have indolent and slow growing disease 
that does not require intervention. Distinguishing between 
patients who would benefit from active surveillance (AS), 
those who require definitive primary treatment, and those 
who require treatment escalation is a challenging and 
evolving issue. 
While clinically-based nomograms and algorithms 
have greatly improved risk stratification in PCa, over the 
last decade there has been a rapid expansion in the field 
of prognostic and predictive biomarker assays. There are 
now several FDA approved biomarkers and commercially 
available clinical laboratory improvement amendments-
based (CLIA) tests to help guide clinicians and patients 
in deciding whether or not biopsy screening is necessary, 
patients on active surveillance require repeat biopsy, patients 
require radical prostatectomy (RP) or radiation therapy (RT) 
as primary treatment, or prognosis for patients who have 
undergone RP or RT with or without androgen deprivation 
therapy (ADT).
In this review, we aim to give an update on the current 
status of liquid and tissue-based FDA-approved and CLIA-
based tests available in the United States, the validation 
studies that led to their development, as well as current 
shortcomings and gaps in knowledge that exist in the field. 
Non-invasive liquid biomarkers
Biomarker tests which sensitively and specifically detect 
clinically significant prostate cancer from blood or urine 
samples continue to be pursued. Compared to tissue-based 
assays liquid biomarkers have minimal risks, as transrectal 
prostate biopsy carries with it the potential risk of infection 
and sepsis (2-4). Therefore, the development of novel, 
non-invasive assays is of great value and importance in the 
diagnosis and management of PCa. In the following section, 
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we will outline the status of non-invasive urine and serum-
based biomarkers which have been develop towards this 
effort (Figure 1).
Prostate specific antigen (PSA)-related liquid biomarkers
PSA
Prostate specific antigen is the most commonly used 
biomarker for the management of PCa today. In the 1980’s 
PSA was introduced as a biomarker of prostate tissue. Due 
to the higher sensitivity of PSA relative to prostatic acid 
phosphatase (PAP) for the detection of PCa, the FDA 
approved the use of PSA for PCa screening in 1994. Upon 
its adoption, the upper limit of normal PSA serum level was 
considered 4.0 ng/mL, although it has since been discovered 
that approximately 20% of cancers are in patients with PSA 
levels <4.0 ng/mL (5,6). 
PSA is a secreted protein expressed from the gene 
kallikrein 3. It exists in several isoforms in blood, urine, and 
semen, all of which are detected by the FDA-approved PSA 
test. It is expressed in both benign and malignant tissue, 
and there are several causes for an elevated serum PSA 
that are not associated with PCa risk (7-9). These include 
inflammation, trauma, and benign prostate hyperplasia 
(BPH). The result of common alternative causes for 
increased PSA reduce the specificity a PCa diagnostic tool. 
Moreover, at 4 ng/mL, the sensitivity and specificity of PSA 
are estimated at 67.5–75.0% and 60.3–70.6% respectively 
(10,11). Although there is much controversy surrounding 
screening practices with PSA, since its widespread adoption, 
mortality from prostate cancer has decreased considerably (1). 
However, the low specificity has also resulted in over-
diagnosis and over-treatment of men with indolent prostate 
cancers that are unlikely to cause morbidity and mortality. 
Metrics related to PSA have also been used to improve 
the sensitivity and specificity of PSA as a biomarker for 
PCa. Increased PSA density (serum PSA/prostate volume) 
has been shown to be associated with increased risk of PCa 
compared to BPH, and risk of higher pathological stage 
and cancer agressiveness (12,13). Shorter PSA doubling 
time and PSA velocity have been shown to be associated 
with increased risk of prostate cancer specific mortality and 
Figure 1 Prostate cancer biomarker assays and the clinical decision-points in which they have been validated. 
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more aggressive disease course (14,15). PSA stability after 
RP has also been shown to be associated with biochemical 
recurrence following RP (16). 
The compositions of PSA isoforms are also associated 
with PCa risk. PSA is normally complexed with the protein 
antichymotrypsin (ACT) in the blood, with a fraction of 
PSA being uncomplexed in the serum (fPSA) (17). In PCa, 
the percent of fPSA is lower than in patients without PCa. 
%fPSA is FDA approved for use in patients with a PSA 
of 4–10 ng/mL to increase the sensitivity and specificity 
of PSA testing (17). It also increases the sensitivity and 
specificity in lower ranges of PSA (2–4 ng/mL) (18). There 
are drawbacks to fPSA however. It requires processing 
within 24 hours to yield reliable results, and procedures 
such as prostate biopsy or DRE can affect the levels of 
serum fPSA (19,20). Thus, it has been difficult for clinicians 
to adopt and implement fPSA as a screening test in urologic 
practices.
Since the widespread adoption of PSA as a screening 
and monitoring test, a great deal of effort has been made to 
improve the sensitivity and specificity of the serum-based 
marker. The Prostate Health Index and 4kscore utilize 
isoforms of PSA and its precursors to help risk-stratify 
patients with an abnormal PSA.
Prostate Health Index (Beckman Coulter, Brea, CA)
Prostate Health Index (PHI) is a mathematical formula 
developed by Beckman Coulter (Brea, CA) that was 
designed to better identify patients with a slightly elevated 
PSA (2.0–10.0 ng/mL) who are at high risk of harboring 
prostate cancer. The formula incorporates both serum 
[−2]proPSA, which is the primary precursor PSA isoform 
prevalent in malignant tissue than benign prostate tissue, 
and serum free PSA which has been shown to be more 
specific that total tPSA in the detection of PCa (17,21). PHI 
is calculated with the formula [ 2] proPSA tPSA
fPSA
−
× . In a prospective, 
double-blind, multi-institutional case-cohort study, 892 
men without a history of PCa but with a normal DRE, at 
least a 6-core biopsy, and a PSA of 2–10 ng/mL, a PHI of 
at least 80% demonstrated 95% specificity (AUC of 0.703) 
for detecting GS 7 or greater prostate cancer. This metric 
score was better than total PSA and free-to-tPSA (22). 
This result was validated in two separate cohorts of biopsy-
negative men, showing that at sensitivity of 95%, PHI was 
more specific (35%) than either total PSA (17.2%) or free 
PSA (19.4%). With 95% sensitivity and PHI cutoff of 24, 
41% of unnecessary biopsies could have been avoided in 
these cohorts of biopsy-naïve men, while missing very few 
cancers of GS 7 or greater (23). Similar to PHI, the ratio of 
[−2]proPSA/tPSA has been shown to outperform both free-
to-tPSA and tPSA in identifying patients with PCa (24). 
4Kscore test (Opko Lab, Miami, FL)
4Kscore test is an algorithm that combines serum 
concentrations of a “4 kallikrein (4k) panel” [total PSA 
(tPSA), free PSA (fPSA), intact PSA (iPSA), and human 
kallikrein 2 (hK2)], with clinical information (age, DRE 
status, previous biopsy result) to predict the likelihood of 
detecting high-grade PCa (GS ≥7) on prostate biopsy. The 
test was first developed in Europe as part of the European 
Randomized Study of Prostate Cancer Screening (ERSPC), 
where the measurement of tPSA, fPSA, iPSA and hK2 were 
consistently correlated with positive biopsy in separate 
cohorts (25-28). In a cohort of 740 biopsy-naïve with a 
PSA ≥3.0 ng/mL, adding the 4k panel to clinical variables 
increased the AUC from 0.87 (95% CI: 0.78–0.92) to 0.90 
(95% CI: 0.86–0.96) with the primary outcome of high-
grade cancer (29). In a similar group of 262 men, including 
the 4k panel increased the AUC from 0.77 (95% CI: 
0.69–0.85) to 0.87 (95% CI: 0.81–0.93) compared to clinical 
variables alone (27). 
The 4K panel has also been evaluated in men with a 
history of a negative biopsy. In a cohort of 925 men with 
elevated PSA, the addition of the 4k panel increased the AUC 
from 0.76 to 0.87 compared to clinical factors alone (26). 
In this cohort, at a cutoff of 15% risk, 712 repeat biopsies 
could have been avoided while delaying the diagnosis of 3 
cancers of GS 7 or greater. 
Of note, in 2015 a study was performed by Nördstrom 
et al. which compared the diagnostic performance of the 
4k panel, PHI, and a base model of PSA and age. The trial 
included 531 biopsy naïve men with PSA levels between 
3 and 15 ng/mL. The trial showed that 4k and PHI were 
comparable, with AUC’s of 0.718 and 0.711 respectively for 
predicting GS ≥7 cancer. Both algorithms performed better 
than age and PSA for the prediction of high-grade cancer. 
OPKO Health commercialized the 4k panel in the US, 
and sponsored a validation study that included 1,012 men 
undergoing prostate biopsy at 26 independent sites (30-32). 
4Kscore is identical to the 4 kallikrein assays investigated in 
Europe, aside from the inclusion of biopsy history as well 
as different sources for the assays of tPSA, fPSA, iPSA, and 
hK2. The AUC of 4Kscore in the prediction of GS ≥7 was 
0.818 (95% CI: 0.788–0.849) which was slightly improved 
by the addition of a DRE (AUC =0.821; CI 0.794–0.852) 
(30,32). In the cohort of 1,012, using a 4Kscore cutoff of 
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7.5% risk, 360 biopsies could have been avoided while 
missing 16 of 215 aggressive cancers found on biopsy (30). 
4Kscore was also associated with higher grade in patients 
from the same cohort who underwent RP (n=144). 
However, this association was not significant when adjusting 
for D’Amico risk or Cancer of the Prostate Risk Assessment 
(CAPRA) (31). 
The 4k panel has also been studied in the setting of 
active surveillance. As part of the Canary PASS trial, Lin 
et al. carried out using the 4k panel to analyze the serum 
of men on active surveillance. The setting in this study 
is unique from past analyses of the 4k panel, in that the 
assay was used on men already diagnosed with PCa. As a 
predictor for reclassification on active surveillance (GS 6 
to GS ≥7 on a subsequent biopsy), the 4k panel did not 
perform markedly better than PSA when combined with a 
clinical model consisting of age, body mass index, history 
of negative biopsies, percentage of positive biopsy cores, 
and prostate volume (33). At the time of first surveillance 
biopsy, the 4k + clinical model had an AUC of 0.783, while 
the PSA + clinical model had an AUC of 0.740. At the time 
of subsequent biopsies, there was no difference in the AUC 
of the two models. So, while the 4k panel is more accurate 
than clinical factors in the pre-diagnosis setting, there is 
minimal benefit of 4k once clinical tumor parameters are 
known.
Non-PSA liquid biomarkers
A number of non-PSA liquid biomarkers have been 
developed with the goal of improving diagnostic accuracy in 
men with suspicion of prostate cancer. They are detailed in 
the following section. 
PCA3 (Hologic, Marlborough, MA)
The prostate cancer antigen 3 (PCA3) assay from Progensa 
is a urine-based, post-DRE, FDA approved test designed to 
assess the need to re-biopsy men with a previous negative 
biopsy. PCA3 is a long noncoding RNA that is specific 
to malignant prostate tissue, and is overexpressed in 95% 
of prostate cancers with a 66-fold median up-regulation 
(29,34,35). Unlike PSA, PCA3 expression is independent 
of prostate volume (36). Several studies of men post-DRE 
and on active surveillance (AS) observed a strong positive 
correlation between PCA3 levels in the urine and positive 
biopsy on repeat biopsy (36-38). In the trial for FDA 
approval, the post DRE urine samples, and serum from 
466 men with at least 1 prior negative biopsy were analyzed 
for PCA3 and PSA RNA levels. On MVA, PCA3 score [(PCA 
3 RNA copies per mL/PSA RNA copies per mL) ×1,000] of 
greater than 25 was associated with increased risk of positive 
repeat biopsy (OR =4.56; 95% CI: 2.65–7.84; P<0.0001) (36). 
When combined with clinical factors such as age, DRE 
result, family history of PCa, race, serum PSA, and number 
of previous negative biopsies, the AUC of the PCA3 score 
increased from 0.653 to 0.740 (P=0.0007) compared to the 
clinical factors alone. 
In reality, PCA3 did not vastly outperform PSA based 
on a dichotomous cutoff of 25 as proposed in the FDA 
validation trial (36,38,39). However, in a study published by 
Wei et al. PCA3 demonstrated a negative predictive value 
(NPV) for any prostate cancer of 88% on repeat biopsy with 
a cutoff of PCA<20, and a positive predictive value (PPV) 
of 80% on initial biopsy with a cutoff of PCA3>60 (40). 
So, while there may not be tremendous value with a 
single dichotomous cut-off, PCA3 may provide valuable 
information when its value is either very high or very low.
Mi-Prostate Score (MLabs, Ann Arbor, MI)
MiPS is an algorithm developed at the University of 
Michigan that combines urine TMPRSS2:ERG, prostate 
cancer antigen 3 (PCA3), and serum PSA to predict the 
risk of detecting PCa on biopsy. The algorithm uses an 
FDA approved assay in the Progensa PCA3 test (Hologic 
Inc, Bedford, MA, USA), and a clinical-grade assay for 
TMPRSS2:ERG (41). TMPRSS2:ERG is a gene fusion that 
is present approximately 50% of PCa patients. The role of 
TMPRSS2:ERG in the development of PCa is not known (17). 
PCA3 is a long noncoding RNA that is overexpressed 
in 95% of prostate cancers. The median up-regulation 
of PCA3 in PCa is 66-fold (29,35). In the initial study 
demonstrating the utility of PCA3, TMPRSS2:ERG, and 
PSA as combined biomarkers of PCa, serum and post-DRE 
urine samples were collected on 48 men undergoing prostate 
biopsy. The MiPS multivariable algorithm was more 
specific than any of the individual variables, with an AUC 
of 0.88 and a specificity of 90% and an 80% sensitivity (41). 
The MiPS algorithm was validated in larger cohort (n 
=1,225) and demonstrated an AUC =0.751 detecting PCa 
on biopsy, and an AUC =0.772 detecting GS 7 or higher. 
This was significantly better than PSA alone (AUC =0.651 
for GS 7 for high grade cancer). Of note, the validation of 
MiPS did not compare its diagnostic accuracy to that of 
PCA3 alone, which is has already been shown to outperform 
PSA. So while MiPS certainly provides value over PSA 
alone, its value over PCA3 still requires validation. 
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Select MDx (MDx Health, Irvine, CA)
Select MDx is an algorithm that combines clinical factors 
with a urine-based assay for RNA levels of HOXC6 
and DLX1. In the trial that validated the assay to detect 
clinically significant PCa, 519 patients undergoing biopsy 
were prospectively enrolled as the training cohort. A post-
DRE urine sample was analyzed for the expression of five 
known markers of PCa and KLK3 (as a control RNA) (42). 
Of the five markers, combining HOXC6 and DLX1 
resulted in the highest AUC (0.76; 95% CI: 0.71–0.81) with 
the primary outcome of GS ≥7 on biopsy. Of note, PCA3 
(AUC =0.68) was also included in the analysis. However, 
HOXC6 and DLX1 more reliably predicted clinically 
significant PCa. The Select MDx metric was validated 
in a separate cohort (n=386) in which the combination 
of HOXC6 and DLX1 had an AUC of 0.73 (95% CI: 
0.67–0.78). In the final model that included PSAD, DRE, 
PSA, age, history of biopsy, and family history of PCa, 
the AUC was 0.90 (0.87–0.93) for high-grade PCa. In the 
validation cohort the NPV was 94%, confirming the clinical 
utility of the biomarkers in reliably predicting patients that 
are unlikely to have clinically significant PCa (43). It should 
be noted that markers such as Select MDx and 4kscore 
provide an advantage over markers such as PHI, in that they 
incorporate clinical variables into their algorithm to be used 
as a single metric. 
ExoDx Prostate Intelliscore (Exosome Diagnostics, 
Waltham, MA)
ExoDx Prostate Intelliscore (EPI) is a pre-biopsy RNA-
based assay which uses the expression of PCA3 and ERG 
isolated from urinary exosomes as a predictor of men 
who will have GS 7 or greater PCa on diagnostic biopsy. 
Exosomes are vesicles secreted by cells, and contain 
proteins, RNA, and other molecules which are closely 
representative of the content of cellular origin (44). PCa 
cells secrete more exosomes than non-cancerous cells of the 
prostate, and in cell-lines from other cancer types, it has 
been shown that the RNA which is secreted in exosomes 
can be upregulated several hundred-fold when compared 
to the cell of origin (45). It has been previously shown that 
post-DRE urine samples contain exosomes with PCA3 
and TMPRSS2: ERG mRNA (44). However, EPI does 
not require a DRE to isolate the exosomal RNA, which is 
a potential benefit to patients undergoing testing. EPI was 
validated in a training cohort of 255 men and a validation 
cohort of 519 men who met the following criteria: age ≥50, 
PSA 2–10 ng/mL, and never having undergone prostate 
biopsy prior to study participation (46). They looked at 
the performance of the assay to predict GS ≥7 on prostate 
biopsy, and found in the validation cohort that when EPI 
was combined with clinical characteristics of age, PSA, race, 
and family history of prostate cancer, EPI demonstrated an 
AUC of 0.73 (95% CI: 0.68–0.77) compared to the AUC of 
0.63 (95% CI: 0.58–0.68) of clinical characteristics alone. 
With the authors’ proposed cutoff, the model yielded a 
sensitivity, specificity, PPV, and NPV of 91.89, 33.96, 35.70, 
and 91.30, respectively, in the validation cohort. If used as a 
determinant of who should and should not get a biopsy, EPI 
could have reduced the number of biopsies by 27% while 
missing 5% of dominant Gleason pattern 4 or greater PCa. 
Tissue-based biomarkers
While great strides have been made in the development of 
“liquid” biomarkers, tissue-based assays remain the gold 
standard for accurately representing the tumor environment 
in PCa. In the last several years, tissue-based biomarkers 
have become standard of care for patients undergoing 
biopsy and radical prostatectomy. Confirm MDx, Decipher, 
Prolaris, and OncotypeDx GPS are now recommended 
by the Molecular Diagnostic Services Program which 
aims to identify and establish coverage and insurance 
reimbursement for molecular diagnostic tests. In addition, 
these tests and are now included in the NCCN guidelines 
for the management of PCa, which is not yet the case for 
liquid biomarker assays. A challenging aspect of these tests 
however, is that they are validated in many of the same 
contexts. Just like in the pre-diagnosis setting, deciding 
which test a physician should utilize after prostate biopsy 
or RP remains challenging. In the following section we 
will review in which contexts these assays were originally 
designed and validated, as well as other contexts in which 
they may play a useful role in patient management (Table 1).
Confirm MDx (MDx Health, Irvine CA)
Confirm MDx is an epigenetic-based assay that was 
developed to aid in the management of patients who have 
a history of a negative biopsy and are considering re-
biopsy (47-49). MDx utilizes a modified polymerase chain 
reaction (multiplex quantitative methylation specific PCR) 
to determine the DNA methylation status of three known 
tumor suppressor genes, GSTP1, APC, and RASSF1. The 
assay is based on the hypothesis that normal tissue adjacent 
to a tumor may harbor epigenetic, genetic, or protein 
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expression changes, and that monitoring the state of these 
non-tumor cells can decrease the likelihood of a false-
negative result on biopsy (70). The initial study used to 
develop Confirm MDx analyzed samples from 498 subjects 
of the MATLOC (Methylation Analysis to Locate Occult 
Cancer) study who had a negative initial screening biopsy 
and a repeat biopsy that was either positive or negative. 
The Confirm MDx assay was associated with a NPV of 
90% (95% CI: 87–93%), and in an MVA controlling for 
age PSA, DRE, and first biopsy result, the epigenetic assay 
was independently associated with cancer detected on 
repeat biopsy (OR 3.17; 95% CI: 1.81–5.53) (47). In the 
DOCUMENT multicenter trial, 350 patients with negative 
screening biopsy underwent the epigenetic assay. A negative 
epigenetic assay was associated with a NPV of 88% (95% 
CI: 85–91%), and an OR of 2.69 (95% CI: 1.60–4.51) 
in an MVA (48). The cohorts from the MATLOC and 
the DOCUMENT trials were combined to evaluate the 
association between DNA-methylation intensity and 
diagnosis of GS ≥7 on repeat biopsy. Confirm MDx was 
associated with a NPV of 96%, and in methylation positive 
men, the degree of methylation was significantly higher in 
those with GS ≥7 compared to those with GS ≤6 (49). 
Prolaris (Myriad Genetics Inc., Salt Lake City, UT)
Prolaris is a gene expression assay that measures the 
expression of 31 cell cycle progression (CCP) genes and 
15 housekeeping genes. The test has been validated 
in prostate needle biopsies as well as RP samples in its 
association with 10-year prostate cancer-specific mortality 
risk (64-69). The initial study compared patients with PCa 
undergoing transurethral resection of the prostate (TURP) 
with patients undergoing RP. In the 366 patients who 
underwent RP, each unit increase in CCP was associated 
with biochemical recurrence on univariate (HR: 1.89; 
95% CI: 1.54–2.31; P<0.0001) and multivariate analysis 
(HR: 1.77; 95% CI: 1.40–2.22; P<0.0001). In the TURP 
cohort, each unit increase (equivalent to a doubling of gene 
expression) in CCP was associated with prostate specific 
mortality on univariate (HR: 2.92; 95% CI: 2.38–3.57; 
P<0.0001) and multivariate analysis (HR: 2.56; 95% 
CI: 1.85–3.53; P<0.001) (64). In a study of 413 post-RP 
patients, a combination of CAPRA-S and CCP scores was 
more closely associated with recurrence risk compared to 
either of the metrics alone (65). 
CCP was also validated in biopsy samples in a cohort 
managed by AS. In this cohort of 349, a one-unit increase 
in CCP was associated with PCa-specific mortality on 
univariate (HR: 2.02; 95% CI: 1.62–2.53; P<0.0005) 
and multivariate analysis (HR: 1.65; 95% CI: 1.31–20.9; 
P<0.0001) controlling for clinical variables (66). In a 
cohort of 141 men who underwent external beam radiation 
therapy as primary curative therapy, CCP score on needle 
biopsy samples was associated with increased risk of 
biochemical recurrence on univariate (HR: 2.55; 1.43–4.55; 
P=0.0017) and multivariate analysis (HR: 2.11; 1.05–4.25; 
P=0.034) when controlling for clinical variables including 
combination ADT and EBRT (57). 
Decipher RP and Decipher Biopsy (GenomeDx, Vancouver 
BC, Canada)
Decipher is a 22-gene panel developed by GenomeDx 
(Vancouver BC, Canada) as a genomic classifier (GC) 
prediction model for metastasis (60). Transcriptome-wide 
RNA microarray sequencing including more than 240,000 
known protein coding genes and non-protein coding RNAs 
was performed on 545 RP samples from patients with 
median follow-up of 16.9 years. Patients were classified into 
three groups: no biochemical recurrence (BCR) or clinical 
metastasis within 5 years of RP, BCR within 5 years of RP 
with no clinical metastasis, or clinical metastasis within 
5 years and used in training and validation sets. Logistic 
regression of the microarray results yielded 43 RNA 
transcripts that were differentially expressed between cases 
and controls, of which 22 improved the performance of a 
random forest machine learning algorithm in the GC. These 
22 biomarkers include both protein coding and non-coding 
RNAs, with roles in cell proliferation, cell-cycle progression, 
immune response, cell structure, cell adhesion, and 
motility, as well as three genes with unknown function. The 
22-gene model yielded an AUC of 0.90 and 0.75 in the 
training and validation sets respectively, which was better than 
any individual clinical or genomic variable on its own (60). 
The decipher GC has also been validated in a high-risk group 
of PCa patients (PSA >20 ng, Gleason ≥8, pT3b, or Mayo 
Clinic nomogram score of 10 or greater), where the AUC of 
the GC was 0.79 for predicting 5-year metastasis after RP. 
When stratified into low, intermediate, and high GC scores, 
the incidence of metastasis in this high-risk group was 2.4%, 
6.0%, and 22.5% respectively (P<0.001) (61). 
Recently, the first individual patient level meta-analysis 
has been performed for Decipher of various risk groups 
of patients undergoing RP. This meta-analysis by Spratt 
et al. demonstrated that Decipher independently was 
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prognostic for the development of metastasis. This finding 
was maintained when looking at subgroups by race, clinical 
or pathologic subgroups, and treatment subgroups using 
adjuvant or salvage therapies (71). 
High decipher GC scores have been validated on biopsy 
cores as a predictor of metastasis and prostate cancer specific 
mortality within 10 years of RP or RT. On multivariate 
analysis (MVA), an increase in biopsy decipher score of 
0.1 (scored 0–1.0) was associated with an increased risk of 
metastasis (HR: 1.72; 95% CI: 1.07–2.81; P=0.02) (50). 
In 100 patients with intermediate and high-risk PCa who 
underwent RT and ADT as primary treatment, each 0.1 
unit increase in GC score associated with time to distant 
metastasis on multivariable analysis (HR: 1.36; 95% CI: 
1.10–1.84; P=0.006) after adjusting for clinical variables (51). 
In the MVA, neither CAPRA, NCCN, nor Gleason score 
were statistically significant in their association with time 
to metastasis. The survival C-index (5 years post-RT) for 
Biopsy decipher, CAPRA, and NCCN, were 0.76 (0.57–0.89), 
0.45 (0.27–0.64), and 0.63 (0.4–0.78) respectively in this 
cohort.
The Decipher test has also been used to develop a novel 
clinical-genomic NCCN risk grouping system (72). Using 
nearly 7,000 patients, including nearly 1,000 prospective 
biopsy samples, pre-treatment clinical-genomic risk groups 
were trained and validated for both metastasis and PCSM. 
In the validation cohort the AUC to predict metastasis 
was approximately 0.6–0.7 for NCCN or CAPRA, which 
increased to 0.84 for the clinical-genomic risk groups. 
A benefit of the technology from GenomeDx, is their 
ability to look at other RNA expression signatures, which 
may be associated with outcomes beyond the scope of 
their original gene expression panel. Retrospectively, 
GenomeDx has used their technology to identify signatures 
related to other treatment modalities such as radiation, 
androgen deprivation therapy (ADT), chemotherapy 
sensitivity (62,63). The Post-Operative Radiation Therapy 
Outcomes Score (PORTOS) score is a 24-gene panel that 
was developed to predict response to RT following RP. 
RT patients were retrospectively matched with patients 
who had not received radiation, controlling for Gleason 
score, PSA, concentration, surgical staging, and treatment 
ADT. In a training cohort of 198 patients, 1,800 DNA 
damage repair and radiation response genes were ranked 
using an Affymetrix Human Exon 1.0 ST microarray 
(Affymetrix, Santa Clara, CA). 24 genes were identified 
that were predictive of EBT response. In patients with 
a high PORTOS score, those who underwent RT had 
decreased incidence of metastasis compared to those who 
did not (HR: 0.12; 95% CI: 0.03–0.41; P<0.0001). In 
patients with a low PORTOS score, those who received 
RT had an increased incidence of metastasis compared to 
those who did not undergo radiotherapy (HR: 2.6; 95% 
CI: 1.6–4.1; P<0.0001). A similar trend was seen in the 
validation cohort where high PORTOS (HR: 0.15; 95% 
CI: 0.04–0.60; P=0.0020) was associated with decreased 
incidence of metastasis with radiation. However, in this 
cohort, the response in the low PORTOS score group 
(HR: 0.92; 95% CI: 0.56–1.51; P=0.76) was not significant. 
PORTOS represents the first gene panel of its kind, 
in that it is a predictive biomarker panel rather than 
prognostic. PORTOS has yet to be validated prospectively 
in a randomized control trial, and its association with 
RT sensitivity has only been shown in post-RP patients. 
Therefore, more investigation is required to validate the 
gene panel prospectively, and also in the setting of RT for 
primary treatment of prostate cancer. 
Another prognostic and predictive biomarker that 
has resulted from the Decipher platform is PAM50 
which has identified three primary subtypes of prostate 
adenocarcinoma. PAM50 was originally developed to 
subtype breast cancer into luminal and basal subtypes. The 
same clustering signature was used to identify luminal A, 
luminal B, and basal subtypes in prostate cancer (62). In a 
study of 3,728 patients, it was discovered that patients with 
the luminal B subtype demonstrated the poorest clinical 
prognosis, with greater risk of biochemical recurrence, 
prostate cancer specific mortality, development of distant 
metastases, and worse overall survival. PAM50 subtyping 
also predicts response to ADT. In a sub-analysis of 315 post-
RP patients who were matched for clinical characteristics 
and compared for response to ADT (210 men who did not 
receive ADT, and 105 who did), luminal B subtype predicted 
response to ADT. 33% of men with luminal B cancers 
who were treated with ADT went on to develop distant 
metastasis vs. 55% in the no ADT controls (P=0.06) (62). 
Remarkably, the same subtypes can be identified even 
among men with histologically homogeneous, low-risk 
tumors. (Cooperberg et al. Eur Urol in press) Similar to 
PORTOS, PAM50 has not been validated prospectively 
for response to ADT based on luminal/basal subtyping. 
However, it certainly warrants more investigation, as 
predicting response to ADT would be incredibly valuable 
for clinicians. The use of PAM50 is being incorporated 
into the currently open phase 2 randomized NRG GU-
006 to prospectively assess the prognostic and predictive 
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capacity of this biomarker for men undergoing post-
operative radiotherapy and the benefit of hormone therapy 
by subtype.
Oncotype Dx (Genomic Health, Redwood City, CA)
Oncotype Dx Genomic Prostate Score (GPS) is based 
on the levels of expression of 17 genes in tissue obtained 
by needle biopsy and is designed to help guide treatment 
decisions in men who are considering active surveillance 
(AS) vs. primary treatment (52). To identify the seventeen 
genes used in the assay, the expression levels of 727 genes 
were analyzed in a group of patients that had undergone 
RP (n=441). Controlling for GS and AUA risk, expression 
changes for 198 of the genes correlated with recurrence, 
PCa death, and adverse pathology at prostatectomy in both 
unifocal and multifocal disease. For validation in needle 
biopsy samples, the expression of 81 of the genes associated 
with aggressive disease from the RP cohort were analyzed 
in 167 AUA low- and intermediate-risk patients with both 
biopsy and RP samples. Of the 81 genes, 58 positively 
correlated with adverse pathology at RP, and consistency 
between the biopsy and RP samples. From the 58 genes, 
12 genes were selected based on their consistency across the 
various samples, reproducibility based on high expression 
and dynamic range, and possible relationship to four 
pathways known to be involved in PCa progression (stromal 
expression, cellular organization, androgen pathway, and 
proliferation). These expression patterns are combined with 
five reference genes in an algorithm to yield a Genomic 
Prostate Score (GPS) (53). 
To assess the utility of GPS as an aid to decision making 
in patients on AS, a validation study at the University of 
California San Francisco was performed on 395 patients 
who underwent RP, but met criteria for AS. In these 
patients, GPS was a significantly associated with pathologic 
stage and grade on RP (OR: 2.1; 95% CI: 1.4–3.2; 
P<0.001). Combining GPS and CAPRA improved the AUC 
(0.67) for favorable pathology compared to CAPRA alone 
(52). In a single independent validation cohort, GPS score 
was determined in the biopsies 431 men. In a multivariate 
analysis, each 20-unit increase in GPS (scored 0–100) was 
associated with time to biochemical recurrence (HR: 2.7; 
P<0.001), and adverse pathology (OR: 3.3; P<0.001) on RP 
in both Caucasian and African American men (54). Of note, 
a 20-unit increased in GPS represents a dramatic difference, 
as the independent validation study showed IQR’s with 
magnitudes of 15–17 GPS units. As a result, a 20-unit 
increase may not be the most clinical valuable metric for 
GPS. In addition, while GPS was validated in patients 
that were eligible AS who underwent RP, GPS has yet to 
be validated in an actual AS cohort. However, preliminary 
analysis would suggest that GPS is associated with biopsy 
upgrade (GS 6 to GS ≥7 on subsequent biopsy) (72). 
Promark (Metamark Genetics, Waltham, MA)
Promark is an automated immunofluorescence-based assay 
designed to guide treatment decisions in men with GS 
3+3 or GS 3+4 cancer (56,58,59). Promark measures the 
expression of eight proteins (DERL1, CUL2, SMAD4, 
PDSS2, HSPA9, FUS, phosphorylated S6, and YBOX1) 
associated with adverse pathology on RP, defined as surgical 
GS ≥3+4, or nonlocalized disease (> T3a, ≥ N1, or ≥ M1). 
The design of Promark addresses inconsistency in biopsy 
samples that is a consequence of the expected variability 
in sample constitution and pathologist discordance in 
Gleason scoring (73,74). The Promark analysis identified 
the areas of lowest and highest grade in the biopsies of 380 
patients who had undergone RP and had long-term follow-
up data, and quantified the expression of 39 candidate 
proteins that had known biological relevance for cancer. 
These 39 proteins were evaluated for antibody specificity, 
signal intensity, dynamic rage, and stability, and 12 were 
identified as significantly associated with adverse pathology 
on RP, and prostate cancer specific mortality in both the 
low-grade and high-grade biopsy samples on univariate and 
multivariate analysis. The AUC with the primary outcome 
of adverse pathology on RP was 0.72 (95% CI: 0.64–0.79) 
in low-grade biopsies, and 0.70 (95% CI: 0.62–0.77) in 
the high-grade biopsies (65). From the 12-gene panel, an 
8 biomarkers assay was validated in its association with 
adverse pathology on RP specifically in GS 3+3 and GS 
4+4 biopsy samples. The AUC for favorable pathology 
prediction when combined with NCCN and D’Amico risk 
stratification were 0.75 (95% CI: 0.69–0.81) and 0.75 (95% 
CI: 0.69–0.81), respectively. 
Conclusions
In this review, we have highlighted the numerous biomarker-
based clinical tests which are available at nearly every stage of 
PCa. From pre-diagnosis, to post-primary treatment, it can 
be challenging for patients and clinicians alike to navigate 
the spectrum of tests available. While these tests offer 
considerable information to guide treatment decisions, they 
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also can be costly and contribute to financial toxicity.
One population in which there are currently no 
prospectively validated liquid or tissue-based biomarker 
assays is patients on active surveillance. Once patients enroll 
on active surveillance, continual surveillance with annual 
or biannual biopsy is burdensome and costly to payers and 
patients. It would be incredibly valuable to have validated 
prognostic biomarkers which might allow for the delay of 
screening biopsy with a strong NPV, or predict patients that 
are likely to fail active surveillance with a strong PPV. 
To date there are also no head-to-head studies comparing 
the prognostic capabilities of tests like Decipher and 
Prolaris, which can be used in the same patient population 
and provide risk projections of similar outcomes. To 
determine which biomarker assays are the most effective 
at each stage of disease progression would ideally require 
randomized control trials and would take years to decades 
of follow-up to determine outcomes. Systematic analysis 
of markers via prospective registries may help demonstrate 
the extent to which markers do or do not improve decision-
making and outcomes. In the coming years, it is important 
for clinicians to stay aware of the developments of this 
rapidly-growing field, as choosing the right test for the 
right patient may become an increasingly nuanced decision.
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